Tegocup 25 mg (Tegoprazan)

Adult dose

1. Treatment of erosive gastroesophageal reflux disease Administer 50 mg orally once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, administer for an additional 4 weeks. 2. Treatment of non-erosive gastroesophageal reflux disease Administer 50 mg orally once daily for 4 weeks. 3. Treatment of gastric ulcers Administer 50 mg orally once daily for 8 weeks. 4. Combination therapy with antibiotics for Helicobacter pylori eradication in patients with peptic ulcers and/or chronic atrophic gastritis Patients with Helicobacter pylori infection should receive eradication therapy. Administer this product 50 mg, amoxicillin 1 g, and clarithromycin 500 mg orally twice daily for 7 days. 5. Maintenance therapy following treatment of erosive gastroesophageal reflux disease <25mg only> Administer 25 mg orally once daily. This product may be administered with or without food.

This medication should not be used in patients with hypersensitivity to this drug or its components, or to benzimidazole. Furthermore, it should not be used concurrently in patients taking certain antiviral medications like atazanavir, nelfinavir, or rilpivirine. It is also safer for pregnant or lactating women to avoid using this medication. There is insufficient experience with this medication in patients with liver or kidney dysfunction, so caution is necessary, and elderly patients should also be treated with care. During the use of this medication, gastrointestinal symptoms such as nausea, diarrhea, dyspepsia, or neurological adverse reactions such as headache and dizziness may occur. Rarely, various side effects such as skin rash, changes in blood tests, fatigue, and muscle pain have been reported, so if any abnormal symptoms persist, consult a physician. This medication suppresses gastric acid secretion, and long-term use may pose a risk of vitamin B12 deficiency, thus regular checks are necessary. Since suppression of gastric acid may slightly increase the risk of bacterial infection in the gastrointestinal tract, notify healthcare professionals if diarrhea persists. Additionally, this medication may interact with certain drugs, so it is essential to inform the doctor or pharmacist if taking other medications. The effects on driving or operating machinery are unclear, but caution is needed due to possible adverse effects of this medication. Long-term use of this medication may increase the risk of gastric polyp or osteoporosis-related fractures, so treatment should be limited to the necessary minimum duration and dose. The safety and efficacy in children and adolescents have not been sufficiently confirmed, so caution is warranted in usage. No serious symptoms have been reported in cases of overdose, but if overdose is suspected, visit a medical facility immediately for appropriate treatment. This medication should be stored out of reach of children and it is advisable to avoid transferring it to other containers.

• Nausea
• diarrhea
• dyspepsia
• nasopharyngitis
• viral upper respiratory infection
• chest discomfort
• epigastric pain
• abdominal discomfort
• constipation
• abdominal pain

This medication should be stored in a tightly closed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature. Proper storage will help maintain the effectiveness and safety of the medication.

Appearance

Pale pink oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle